首页> 外文OA文献 >Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

【2h】

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

机译：Neoadjuvant反编程死亡-1免疫疗法通过Pembrolizumab在可重演的节点阳性阶段II / IIIa非小细胞肺癌（NSCLC）：Neomun试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Florian Eichhorn; Laura V. Klotz; Helge Bischoff; Michael Thomas; Felix Lasitschka; Hauke Winter; Hans Hoffmann; Martin E. Eichhorn;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial [J] . Florian Eichhorn, Laura V. Klotz, Helge Bischoff, BMC Cancer . 2019,第1期

机译：Neoadjuvant反编程死亡-1免疫疗法通过Pembrolizumab在可重演的节点阳性阶段II / IIIa非小细胞肺癌（NSCLC）：Neomun试验
2. Standardized Uptake Decrease on [F-18]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer [J] . Poettgen Christoph, Gauler Thomas, Bellendorf Alexander, Journal of Clinical Oncology . 2016,第21期

机译：新辅助化疗后[F-18]-氟脱氧葡萄糖正电子发射断层显像的标准化摄取减少是多模式治疗后长期预后的分类指标：可切除的IIIA / B期非小细胞肺癌随机试验的次级分析
3. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial [J] . Guberina M., Eberhardt W., Stuschke M., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第5期

机译：心脏剂量暴露作为预后标志物放射治疗，可重新切除阶段IIIA / B非小细胞肺癌：随机试验的二次分析
4. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
5. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial [O] . Florian Eichhorn, Laura V. Klotz, Helge Bischoff, 2019

机译：NEOMUN试验：Pembrolizumab用于可切除的淋巴结阳性的II / IIIa期非小细胞肺癌（NSCLC）的新辅助抗程序死亡1免疫疗法
6. 126TiP SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC): A multicenter single-arm phase II trial [O] . S.I. Rothschild, A. Zippelius, S. Savic Prince, 2018

机译：126TIP SAKK 16/14：抗PD-L1抗体Durvalumab（Medi4736）除了IIIa阶段（N2）非小细胞肺癌（NSCLC）的Neoadjuvant化疗之外：多中心单臂期II试验

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

著录项

引文网络

相似文献

相关主题

期刊订阅